John Durant, MD
General Practice · Dadeville, ALNPI 1790717858
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 281 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 27.2% of the total. Reporting peaked in 2023 at $850 and has fallen 50.7% since, to $419 in 2025. Among general practice clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$1K
- Bayer$532
- AstraZeneca$249
- Pfizer$184
- Novo Nordisk$169
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,61399%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 97 | $1,271 |
| GSK | 68 | $1,084 |
| Bayer | 27 | $532 |
| AstraZeneca | 7 | $249 |
| Pfizer | 10 | $184 |
| Novo Nordisk | 9 | $169 |
| Otsuka America Pharmaceutical, Inc. | 7 | $136 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $86 |
| Amgen | 6 | $85 |
| Indivior Inc. | 3 | $77 |
| Sunovion Pharmaceuticals Inc. | 4 | $70 |
| Novartis | 4 | $69 |
| Astellas Pharma US Inc | 1 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Neurocrine Biosciences, Inc. | 3 | $56 |
| Mylan Specialty L.p. | 3 | $52 |
| Axsome Therapeutics, Inc. | 3 | $49 |
| Johnson & Johnson | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Boehringer Ingelheim | 1 | $28 |
| Lundbeck LLC | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Edwards Lifesciences | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$111
How this compares
$4,678 in reported general payments places this provider in the 95th percentile of 1,114 general practice providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $90,818 |
| EliquisApixaban | 94 | $76,321 |
| RexultiBrexpiprazole | 35 | $61,102 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $60,391 |
| MounjaroTirzepatide | 46 | $49,203 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 58 | $40,964 |
| FarxigaDapagliflozin Propanediol | 49 | $40,013 |
| JardianceEmpagliflozin | 37 | $37,533 |
| JanuviaSitagliptin Phosphate | 36 | $34,360 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $27,431 |
| RybelsusSemaglutide | 17 | $25,888 |
| TrulicityDulaglutide | 20 | $25,153 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 36 | $24,023 |
| LinzessLinaclotide | 23 | $21,450 |
| Nurtec OdtRimegepant Sulfate | 11 | $12,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $169 | $116,706107 claims |
| PfizerEliquis, Nurtec Odt | $184 | $88,334105 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $249 | $84,041118 claims |
| Lilly USA, LLCMounjaro, Trulicity | $12 | $74,35666 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,084 | $70,105106 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $28 | $61,55673 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $136 | $61,10235 claims |
| AbbVieLinzess, Synthroid | $1,271 | $23,90744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,114 general practice providers in Alabama.
Other general practice in Dadeville
- Robert SchusterDadeville$12K
- Frank TombrelloBirmingham$163K
- Bradley WillisMontgomery$151K
- Ashley McIntyreMontgomery$123K
- John BurgessBirmingham$117K
- Glenn HarnettHoover$113K
- Alan ColemanAthens$30K
- Darrell DoucetteHuntsville$20K
- Earl RogersMobile$19K
- Jennifer DoobrowCullman$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.